NovAccess Global Inc. (XSNX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.46 Million USD | 80.37% |
| 2022 | 1.36 Million USD | -49.33% |
| 2021 | 2.69 Million USD | 225.61% |
| 2020 | 828.89 Thousand USD | 52.01% |
| 2019 | 545.27 Thousand USD | 27.22% |
| 2018 | 428.61 Thousand USD | -5.47% |
| 2017 | 453.39 Thousand USD | -6.4% |
| 2016 | 484.38 Thousand USD | -7.82% |
| 2015 | 525.45 Thousand USD | -3.17% |
| 2014 | 542.65 Thousand USD | -45.4% |
| 2013 | 993.93 Thousand USD | 22.72% |
| 2012 | 809.92 Thousand USD | -36.1% |
| 2011 | 1.26 Million USD | -31.52% |
| 2010 | 1.85 Million USD | -53.48% |
| 2009 | 3.97 Million USD | -6.65% |
| 2008 | 4.26 Million USD | 61.0% |
| 2007 | 2.64 Million USD | -21.58% |
| 2006 | 3.37 Million USD | 144.03% |
| 2005 | 1.38 Million USD | -9.45% |
| 2004 | 1.52 Million USD | 947.54% |
| 2003 | 145.84 Thousand USD | 208.36% |
| 2002 | 47.29 Thousand USD | 178.37% |
| 2001 | 16.99 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 232.55 Thousand USD | -9.7% |
| 2024 Q1 | 257.54 Thousand USD | -37.19% |
| 2024 Q3 | 315.34 Thousand USD | 35.6% |
| 2023 FY | 2.46 Million USD | 80.37% |
| 2023 Q1 | 517.11 Thousand USD | 76.21% |
| 2023 Q4 | 410.01 Thousand USD | -15.4% |
| 2023 Q3 | 484.64 Thousand USD | -54.06% |
| 2023 Q2 | 1.05 Million USD | 104.01% |
| 2022 Q4 | 293.46 Thousand USD | -9.68% |
| 2022 Q1 | 322.32 Thousand USD | -37.56% |
| 2022 Q2 | 426.94 Thousand USD | 32.46% |
| 2022 Q3 | 324.91 Thousand USD | -23.9% |
| 2022 FY | 1.36 Million USD | -49.33% |
| 2021 Q4 | 516.23 Thousand USD | 2.94% |
| 2021 Q1 | 1.39 Million USD | 1689.91% |
| 2021 Q3 | 501.49 Thousand USD | 78.26% |
| 2021 FY | 2.69 Million USD | 225.61% |
| 2021 Q2 | 281.32 Thousand USD | -79.9% |
| 2020 FY | 828.89 Thousand USD | 52.01% |
| 2020 Q3 | 489.87 Thousand USD | 251.31% |
| 2020 Q2 | 139.44 Thousand USD | 14.44% |
| 2020 Q1 | 121.84 Thousand USD | -12.64% |
| 2020 Q4 | 78.21 Thousand USD | -84.03% |
| 2019 FY | 545.27 Thousand USD | 27.22% |
| 2019 Q1 | 173.82 Thousand USD | 45.47% |
| 2019 Q2 | 111.94 Thousand USD | -35.6% |
| 2019 Q3 | 120.03 Thousand USD | 7.22% |
| 2019 Q4 | 139.47 Thousand USD | 16.2% |
| 2018 Q3 | 95.81 Thousand USD | 0.04% |
| 2018 Q4 | 119.49 Thousand USD | 24.71% |
| 2018 Q1 | 117.53 Thousand USD | 15.96% |
| 2018 Q2 | 95.77 Thousand USD | -18.51% |
| 2018 FY | 428.61 Thousand USD | -5.47% |
| 2017 Q4 | 101.35 Thousand USD | -8.62% |
| 2017 FY | 453.39 Thousand USD | -6.4% |
| 2017 Q3 | 110.92 Thousand USD | -2.84% |
| 2017 Q2 | 114.16 Thousand USD | -10.07% |
| 2017 Q1 | 126.95 Thousand USD | 16.75% |
| 2016 Q2 | 127.79 Thousand USD | 1.82% |
| 2016 Q1 | 125.5 Thousand USD | -5.54% |
| 2016 Q3 | 122.33 Thousand USD | -4.27% |
| 2016 Q4 | 108.74 Thousand USD | -11.12% |
| 2016 FY | 484.38 Thousand USD | -7.82% |
| 2015 FY | 525.45 Thousand USD | -3.17% |
| 2015 Q4 | 132.86 Thousand USD | 5.11% |
| 2015 Q3 | 126.4 Thousand USD | -3.4% |
| 2015 Q2 | 130.85 Thousand USD | -3.31% |
| 2015 Q1 | 135.33 Thousand USD | 15.99% |
| 2014 Q4 | 116.67 Thousand USD | -20.25% |
| 2014 Q1 | 145.91 Thousand USD | -71.02% |
| 2014 FY | 542.65 Thousand USD | -45.4% |
| 2014 Q2 | 133.78 Thousand USD | -8.31% |
| 2014 Q3 | 146.29 Thousand USD | 9.35% |
| 2013 FY | 993.93 Thousand USD | 22.72% |
| 2013 Q4 | 503.43 Thousand USD | 244.36% |
| 2013 Q3 | 146.19 Thousand USD | -21.25% |
| 2013 Q2 | 185.64 Thousand USD | 17.01% |
| 2013 Q1 | 158.65 Thousand USD | 40.06% |
| 2012 Q4 | 113.28 Thousand USD | -54.12% |
| 2012 FY | 809.92 Thousand USD | -36.1% |
| 2012 Q3 | 246.92 Thousand USD | 20.98% |
| 2012 Q2 | 204.09 Thousand USD | -16.91% |
| 2012 Q1 | 245.62 Thousand USD | -16.12% |
| 2011 Q3 | 295.16 Thousand USD | -2.65% |
| 2011 Q1 | 376.21 Thousand USD | 14.78% |
| 2011 Q2 | 303.21 Thousand USD | -19.4% |
| 2011 Q4 | 292.82 Thousand USD | -0.79% |
| 2011 FY | 1.26 Million USD | -31.52% |
| 2010 FY | 1.85 Million USD | -53.48% |
| 2010 Q2 | 564.51 Thousand USD | 6.16% |
| 2010 Q3 | 426.52 Thousand USD | -24.45% |
| 2010 Q1 | 531.75 Thousand USD | -42.58% |
| 2010 Q4 | 327.75 Thousand USD | -23.16% |
| 2009 Q2 | 967.39 Thousand USD | -21.7% |
| 2009 Q4 | 926.14 Thousand USD | 10.98% |
| 2009 Q3 | 834.5 Thousand USD | -13.74% |
| 2009 Q1 | 1.23 Million USD | 37.63% |
| 2009 FY | 3.97 Million USD | -6.65% |
| 2008 Q4 | 897.62 Thousand USD | 21.77% |
| 2008 Q3 | 737.17 Thousand USD | 2.13% |
| 2008 Q2 | 721.78 Thousand USD | -64.28% |
| 2008 Q1 | 2.02 Million USD | 110.93% |
| 2008 FY | 4.26 Million USD | 61.0% |
| 2007 Q2 | 505.77 Thousand USD | -17.96% |
| 2007 Q3 | 566.8 Thousand USD | 12.07% |
| 2007 Q4 | 958.05 Thousand USD | 69.03% |
| 2007 FY | 2.64 Million USD | -21.58% |
| 2007 Q1 | 616.49 Thousand USD | -48.47% |
| 2006 Q3 | 634.68 Thousand USD | 61.88% |
| 2006 Q4 | 1.19 Million USD | 88.52% |
| 2006 Q2 | 392.08 Thousand USD | -74.97% |
| 2006 Q1 | 1.56 Million USD | 114.27% |
| 2006 FY | 3.37 Million USD | 144.03% |
| 2005 Q1 | 164.79 Thousand USD | -87.32% |
| 2005 Q2 | 205.32 Thousand USD | 24.59% |
| 2005 Q3 | 282.27 Thousand USD | 37.48% |
| 2005 FY | 1.38 Million USD | -9.45% |
| 2005 Q4 | 731.01 Thousand USD | 158.97% |
| 2004 Q4 | 1.29 Million USD | 965.15% |
| 2004 Q3 | 122.02 Thousand USD | 89.34% |
| 2004 Q2 | 64.44 Thousand USD | 54.79% |
| 2004 Q1 | 41.63 Thousand USD | -68.31% |
| 2004 FY | 1.52 Million USD | 947.54% |
| 2003 Q4 | 131.4 Thousand USD | 896.51% |
| 2003 FY | 145.84 Thousand USD | 208.36% |
| 2003 Q2 | - USD | -100.0% |
| 2003 Q1 | 1259.00 USD | -95.35% |
| 2003 Q3 | 13.18 Thousand USD | 0.0% |
| 2002 Q4 | 27.08 Thousand USD | 4610.09% |
| 2002 Q1 | 2545.00 USD | -63.58% |
| 2002 Q3 | 575.00 USD | -96.64% |
| 2002 FY | 47.29 Thousand USD | 178.37% |
| 2002 Q2 | 17.09 Thousand USD | 571.67% |
| 2001 Q3 | 6733.00 USD | 442.11% |
| 2001 FY | 16.99 Thousand USD | 0.0% |
| 2001 Q4 | 6987.00 USD | 3.77% |
| 2001 Q2 | 1242.00 USD | -38.79% |
| 2001 Q1 | 2029.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -84.716% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 51.076% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 91.653% |
| Nascent Biotech, Inc. | 2.22 Million USD | -10.623% |
| Rebus Holdings, Inc. | 664 Thousand USD | -271.5% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 93.379% |
| Qrons Inc. | 643.67 Thousand USD | -283.23% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -533.207% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 95.705% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -493.715% |
| Skye Bioscience, Inc. | 13.54 Million USD | 81.792% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.158% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 49.841% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -842.497% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.119% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 15.413% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -64.243% |
| Mesoblast Limited | 5.9 Million USD | 58.205% |
| Marizyme, Inc. | 19.23 Million USD | 87.179% |
| Genus plc | 147.7 Million USD | 98.33% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 71.902% |
| Pharming Group N.V. | 225.49 Million USD | 98.906% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -20.406% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -83.875% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 70.419% |
| ContraFect Corporation | 56.88 Million USD | 95.664% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 44.048% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -66.814% |
| IMV Inc. | 37.7 Million USD | 93.458% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 11.597% |
| MultiCell Technologies, Inc. | 567.42 USD | -434632.826% |
| ONE Bio Corp. | 6.44 Million USD | 61.719% |
| Accustem Sciences Inc. | 3.74 Million USD | 34.157% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.13% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -363.71% |
| Q BioMed Inc. | 3.43 Million USD | 28.221% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 90.019% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 6.118% |
| Biomind Labs Inc. | 994.18 Thousand USD | -148.12% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.517% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -40.183% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 63.281% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -32.311% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 9967.044% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 84.593% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -34.421% |
| GB Sciences, Inc. | 1.42 Million USD | -73.653% |
| Alpha Cognition Inc. | 9.7 Million USD | 74.584% |
| HST Global, Inc. | 140.9 Thousand USD | -1650.631% |
| CSL Limited | 3.44 Billion USD | 99.928% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -119.285% |
| Halberd Corporation | 74.84 Thousand USD | -3195.958% |
| Enzolytics Inc. | 2.17 Million USD | -13.18% |
| Agentix Corp. | 1.37 Million USD | -79.825% |
| Resverlogix Corp. | 12.71 Million USD | 80.595% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 32.431% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.839% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -136.28% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -2.571% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -56.188% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 27.554% |
| AVAX Technologies, Inc. | 7.31 Million USD | 66.256% |
| Zenith Capital Corp. | 8.94 Million USD | 72.417% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.701% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -14059.698% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -0.466% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1338.269% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -28.417% |
| Kadimastem Ltd | 2.41 Million USD | -2.35% |
| Helix BioMedix, Inc. | 1.97 Million USD | -25.087% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 77.3% |
| BioStem Technologies, Inc. | 22.97 Million USD | 89.263% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1259.209% |
| LadRx Corporation | 3.81 Million USD | 35.286% |
| Cell Source, Inc. | 4.32 Million USD | 42.97% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -167.107% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -167.107% |
| Affymax, Inc. | 39.38 Million USD | 93.737% |
| Itoco Inc. | 919.14 Thousand USD | -168.376% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 41.8% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -120.443% |
| Mobile Lads Corp. | 554.54 Thousand USD | -344.825% |
| CytoDyn Inc. | 18.05 Million USD | 86.34% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -9700.791% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1020.858% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -73.741% |
| SYBLEU INC | 160.87 Thousand USD | -1433.331% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -35.811% |
| International Stem Cell Corporation | 5.27 Million USD | 53.201% |
| Bioxytran, Inc. | 3.82 Million USD | 35.428% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4585.918% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -12025.847% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.198% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -52.457% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -235.233% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 20.708% |
| Neutra Corp. | 243.82 Thousand USD | -911.71% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 85.87% |
| PureTech Health plc | 144.59 Million USD | 98.294% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 87.961% |
| IXICO plc | 4.7 Million USD | 47.594% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 71.959% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.905% |
| CSL Limited | 3.89 Billion USD | 99.937% |
| Cellectis S.A. | 97.32 Million USD | 97.465% |